Safety and Efficacy of GSK2248761, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor, in Treatment-Naive HIV-1-Infected Subjects

GSK2248761 is a novel, once-daily (QD), next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) with activity against efavirenz-resistant strains. Two phase I/IIa, double-blind, randomized, placebo-controlled studies investigated the antiviral activity, safety, and pharmacokinetics (PK...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Zala, Carlos, St. Clair, Marty, Dudas, Kathleen, Kim, Joseph, Lou, Yu, White, Scott, Piscitelli, Steve, Dumont, Etienne, Pietropaolo, Keith, Zhou, Xiao-Jian, Mayers, Douglas
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology 2012
Materias:
Antiviral Agents
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3346662/
https://ncbi.nlm.nih.gov/pubmed/22314532
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.05597-11
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares